Treatment of chronic hepatitis C

Yun Jung Chang, Kwan Soo Byun

    Research output: Contribution to journalReview articlepeer-review

    1 Citation (Scopus)


    Chronic infection with HCV represents second most common cause of end-stage liver diseases and hepatocellular carcinoma in Korea. The introduction of new agents and regimens for the treatment of chronic hepatitis C, such as pegylated forms of interferon-alpha (Peg-IFN) and combination with oral ribavirin has resulted in substantial improvement in sustained virologic response (SVR) rates. SVR rate of Peg-IFN and ribavirin combination therapy can be 40-46% of individuals infected with genotype 1 and approximately 75-85% with genotype 2 and 3. Peg-IFN/ribavirin combination therapy represents current standard therapy of chronic hepatitis C. This article reviews the treatment objectives, outcomes, optimal regimens, efficacy and predictors of response, monitoring during treatment, adverse events, retreatment of persons who failed to respond to previous treatments, and treatment of special patient groups in chronic hepatitis C.

    Original languageEnglish
    Pages (from-to)301-307
    Number of pages7
    JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
    Issue number6
    Publication statusPublished - 2004 Dec

    ASJC Scopus subject areas

    • Medicine(all)


    Dive into the research topics of 'Treatment of chronic hepatitis C'. Together they form a unique fingerprint.

    Cite this